Shin Yeu Ong

Dr. Shin Yeu Ong

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 October 2022 in Science Translational Medicine
Verified
Journal Article
Closed access
JGJasmine Goh
Jasmine Goh
SMSanjay De Mel
Sanjay De Mel
MHMichal M. Hoppe
Michal M. Hoppe
MRMasturah Bte Mohd Abdul Rashid
Masturah Bte Mohd Abdul Rashid
XZXi Yun Zhang
Xi Yun Zhang
AJAnand D. Jeyasekharan
Anand D. Jeyasekharan
Although combination therapy is the standard of care for relapsed/refractory non-Hodgkin’s lymphoma (RR-NHL), combination treatment chosen for an individual patient is empirical, and response rates remain poor in individuals with chemotherapy-resistant disease. Here, we evaluate an experimental-analytic method, quadratic phenotypic optimization platform (QPOP), for prediction of patient-specific drug combination efficacy from a limited quantity of biopsied tumor samples. In this prospective study, we enrolled 71 patients with RR-NHL (39 B cell NHL and 32 NK/T cell NHL) with a median of two prior lines of treatment, at two academic hospitals in Singapore from November 2017 to August 2021. Fresh biopsies underwent ex vivo testing using a panel of 12 drugs with known efficacy against NHL to identify effective single and combination treatments. Individualized QPOP reports were generated for 67 of 75 patient samples, with a median turnaround time of 6 days from sample collection to report generation. Doublet drug combinations containing copanlisib or romidepsin were most effective against B cell NHL and NK/T cell NHL samples, respectively. Off-label QPOP-guided therapy offered at physician discretion in the absence of standard options ( n = 17) resulted in five complete responses. Among patients with more than two prior lines of therapy, the rates of progressive disease were lower with QPOP-guided treatments than with conventional chemotherapy. Overall, this study shows that the identification of patient-specific drug combinations through ex vivo analysis was achievable for RR-NHL in a clinically applicable time frame. These data provide the basis for a prospective clinical trial evaluating ex vivo–guided combination therapy in RR-NHL.

2 February 2024 in American Journal of Hematology
Verified
Journal Article
Open access
SOShin Yeu Ong
Shin Yeu Ong
Jasmine M. ZainJasmine M. Zain
Jasmine M. Zain
Introduction: Aggressive T‐cell lymphomas continue to have a poor prognosis. There are over 30 different subtypes of peripheral T‐cell lymphoma (PTCL), and we are now beginning to understand the differences between the various subtypes beyond histologic variations.Molecular Pathogenesis of Various Subtypes of PTCL: Gene expression profiling and other molecular techniques have enabled deeper understanding of differences in various subtypes as reflected in the latest 5th WHO classification of PTCL. It is becoming increasingly clear that therapeutic approaches that target specific cellular pathways are needed to improve the clinical outcomes of PTCL.Targeted Therapies: There are many targeted agents currently in various stages of clinical trials for PTCL that take advantage of the differential expression of specific proteins or receptors in PTCL tumors. This includes the CD30 directed antibody drug conjugate brentuximab vedotin. Other notable targets are phosphatidylinositol 3‐kinase inhibitors, histone deacetylase inhibitors, CD25, and chemokine receptor 4. Anaplastic lymphoma kinase (ALK) inhibitors are promising for ALK expressing tumors.Immunotherapies: Allogeneic stem cell transplant continues to be the curative therapy for most aggressive subtypes of PTCL. The use of checkpoint inhibitors in the treatment of PTCL is still controversial, with best results seen in cases of extranodal natural killer cell/T‐cell lymphoma. Bispecific antibody‐based treatments and chimeric antigen receptor cell‐based therapies are in clinical trials.

5 September 2023 in American Journal of Hematology
Verified
Journal Article
Open access
SOShin Yeu Ong
Shin Yeu Ong
SPStacy Pak
Stacy Pak
MMMatthew Mei
Matthew Mei
YWYan Wang
Yan Wang
LPLeslie Popplewell
Leslie Popplewell
EBElizabeth Budde
Elizabeth Budde
Fludarabine/cyclophosphamide (Flu/Cy) is established for lymphodepletion (LD) prior to standard‐of‐care CAR T‐cell therapy for lymphoma. There is ongoing need to test alternative LD regimens to preserve efficacy, improve safety, and address challenges including the recent national fludarabine shortage. We retrospectively evaluated outcomes among patients with relapsed/refractory aggressive B‐cell lymphoma who received bendamustine (n = 27) or Flu/Cy (n = 42) LD before axicabtagene ciloleucel (axi‐cel) at our institution. The median change in absolute lymphocyte count from pre‐LD to time of axi‐cel infusion was −0.6×109/L in bendamustine cohort and −0.7×109/L in Flu/Cy cohort. The best overall response/complete response rates were 77.8% (95% CI: 57.7%–91.4%)/48.1% (95% CI: 28.7%–68.1%) among bendamustine cohort and 81.0% (95% CI: 65.9%–91.4%)/50.0% (95% CI: 34.2%–65.8%) among Flu/Cy cohort. Six‐month progression‐free survival were 43.8% (95% CI: 24.7%–61.3%) and 55.6% (95% CI: 39.0%–69.3%) in bendamustine and Flu/Cy cohorts, while 6‐month overall survival were 81.5% (95% CI: 61.1%–91.8%) and 90.4% (95% CI: 76.4%–96.3%), respectively. Relative to Flu/Cy‐treated patients, bendamustine‐treated patients did not show an increase in hazards associated with experiencing progression/relapse/death (aHR:1.4 [95% CI: 0.7–2.8]; p = .32) or death (aHR:1.6 [95% CI: 0.5–5.6]; p = .46), after adjusting for baseline number of prior therapies and refractory disease. Any grade/grade ≥3 CRS were observed in 89%/3.7% and 86%/4.8% among bendamustine and Flu/Cy cohorts, while any grade ICANS/grade ≥3 ICANS were observed in 30%/19% and 55%/31% respectively. While more Flu/Cy‐treated patients experienced grade ≥3 neutropenia compared with bendamustine‐treated patients (100% vs. 68%), grade ≥3 infectious complications were comparable (24% vs. 19% respectively). More patients received bendamustine LD and axi‐cel as outpatient than Flu/Cy cohort, without increased toxicities and with shorter median inpatient stays. In conclusion, we observed comparable efficacy and lower any grade ICANS among patients receiving bendamustine relative to Flu/Cy LD, followed by axi‐cel.

12 August 2021 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
SOShin Yeu Ong
Shin Yeu Ong
SMSanjay de Mel
Sanjay de Mel
NGNicholas Francis Grigoropoulos
Nicholas Francis Grigoropoulos
YCYunxin Chen
Yunxin Chen
YTYan Chin Tan
Yan Chin Tan
CNChandramouli Nagarajan
Chandramouli Nagarajan
The role of central nervous system (CNS) prophylaxis with high-dose methotrexate (HDMTX) in DLBCL is controversial. In this retrospective study, we evaluated the efficacy of prophylactic HDMTX on isolated CNS relapse, concomitant CNS and systemic relapse, systemic relapse, and survival outcomes in 226 patients with newly diagnosed DLBCL and high-risk CNS International Prognostic Index (CNS-IPI) score treated with RCHOP. The three-year risk of isolated CNS relapse was significantly lower in patients who received HDMTX, at 3.1% compared to 14.6% (P = 0.032) in those who did not. However, neither concomitant CNS-systemic relapse rates, systemic relapse rates, nor three-year PFS and OS were significantly different between treatment groups in multivariable analysis. Among propensity score-matched patients (N = 102), HDMTX was also associated with significantly lower isolated CNS relapse rates (HR 0.06, 95% CI 0.004–0.946, P = 0.046). HDMTX was well tolerated with manageable toxicities when given at a dose of 3 g/m2 by day 3 of RCHOP chemotherapy. Using propensity score matching and multivariable regression to yield treatment groups with well-balanced covariates, we showed that prophylactic HDMTX improved isolated CNS relapse rates but did not decrease concomitant CNS-systemic relapse rates, systemic relapse rates, or improve survival outcomes.

22 July 2022 in Cancers
Verified
Journal Article
Open access
PDF file
SOShin Yeu Ong
Shin Yeu Ong
MYMelinda Tan Si Yun
Melinda Tan Si Yun
NHNurul Aidah Abdul Halim
Nurul Aidah Abdul Halim
DCDheepa Christopher
Dheepa Christopher
WJWei Ying Jen
Wei Ying Jen
GWGee Chuan Wong
Gee Chuan Wong
The prognostic value of measurable residual disease (MRD) by flow cytometry in acute myeloid leukemia (AML) patients treated with non-intensive therapy is relatively unexplored. The clinical value of MRD threshold below 0.1% is also unknown after non-intensive therapy. In this study, MRD to a sensitivity of 0.01% was analyzed in sixty-three patients in remission after azacitidine/venetoclax treatment. Multivariable cox regression analysis identified prognostic factors associated with cumulative incidence of relapse (CIR), progression-free survival (PFS) and overall survival (OS). Patients who achieved MRD < 0.1% had a lower relapse rate than those who were MRD ≥ 0.1% at 18 months (13% versus 57%, p = 0.006). Patients who achieved an MRD-negative CR had longer median PFS and OS (not reached and 26.5 months) than those who were MRD-positive (12.6 and 10.3 months, respectively). MRD < 0.1% was an independent predictor for CIR, PFS, and OS, after adjusting for European Leukemia Net (ELN) risk, complex karyotype, and transplant (HR 5.92, 95% CI 1.34–26.09, p = 0.019 for PFS; HR 2.60, 95% CI 1.02–6.63, p = 0.046 for OS). Only an MRD threshold of 0.1%, and not 0.01%, was predictive for OS. Our results validate the recommended ELN MRD cut-off of 0.1% to discriminate between patients with improved CIR, PFS, and OS after azacitidine/venetoclax therapy.

5 August 2019 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
SOShin Yeu Ong
Shin Yeu Ong
CPColin Phipps
Colin Phipps
CNChandramouli Nagarajan
Chandramouli Nagarajan
TTTiffany Tang
Tiffany Tang
SLSoon Thye Lim
Soon Thye Lim
YLYuh Shan Lee
Yuh Shan Lee
Central nervous system (CNS) relapse occurs in 2–6% of patients with diffuse large B-cell lymphoma (DLBCL) and is a dismal diagnosis with poor outcomes. The National Cancer Comprehensive Cancer Net...